Most of the FDA-approved antiangiogenesis drugs like Bevacizumab (Avastin), Cetuximab and Panitumumab (INN), formerly ABX-EGF; work by blocking endothelial growth factor receptor (EGFR), which in tern inhibit vascular endothelial growth factor (VEGF), which directly stimulates blood vessel development in tumours.